Tags

Type your tag names separated by a space and hit enter

Cognitive screening in Parkinson's disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) with 3 other short scales.
Rev Neurol (Paris). 2016 Feb; 172(2):138-45.RN

Abstract

BACKGROUND

Cognitive screening is crucial in Parkinson's disease (PD). However, there is still a lack of short tools in French. In this study, we aimed to compare the Parkinson Neuropsychometric Dementia Assessment (PANDA) with the Mini Mental Parkinson (MMP), the Mini Mental State Examination (MMSE) and the Clock Test in French-speaking patients. We also aimed to propose cut-off scores for cognitive impairment and dementia for the French language version of the PANDA.

METHOD

Fifty-one patients with PD took the PANDA, the MMSE, the MMP, and the Clock Test. They also underwent extensive neuropsychological testing by a neuropsychologist who was blinded to the above-mentioned screening test results. Patients were classified as either having normal cognition (n=15), mild cognitive impairment (n=20) or dementia (n=16).

RESULTS

When compared with the three other screening tools, the PANDA exhibited the highest area under the curve (AUC) for both cognitive disorders and dementia. Using the cut-off scores proposed for the German version, the PANDA had 94% specificity and 100% sensitivity for dementia and 100% and 72%, respectively for cognitive disorders.

CONCLUSIONS

In our study, the PANDA exhibited a higher discriminative power than the three other tests in detecting cognitive disorders and dementia. In PD patients, the PANDA should thus be considered for the detection of cognitive impairment in routine clinical practice.

Authors+Show Affiliations

Rehabilitation unit, hôpital fribourgeois Billens, 1, rue de l'Hôpital, 1681 Billens, Switzerland. Electronic address: anne-isabelle.gasser@h-fr.ch.University of Basel, Basel, Switzerland.Institute of Gerontology & Center for Neuropsychological Diagnostics and Intervention (CeNDI), University of Vechta, Vechta, Germany; Department of Neurology, University Clinic Cologne, Cologne, Germany.Department of Neurology, University Clinic Cologne, Cologne, Germany.Rehabilitation unit, hôpital fribourgeois Billens, 1, rue de l'Hôpital, 1681 Billens, Switzerland.

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26494570

Citation

Gasser, A-I, et al. "Cognitive Screening in Parkinson's Disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) With 3 Other Short Scales." Revue Neurologique, vol. 172, no. 2, 2016, pp. 138-45.
Gasser AI, Calabrese P, Kalbe E, et al. Cognitive screening in Parkinson's disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) with 3 other short scales. Rev Neurol (Paris). 2016;172(2):138-45.
Gasser, A. I., Calabrese, P., Kalbe, E., Kessler, J., & Rossier, P. (2016). Cognitive screening in Parkinson's disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) with 3 other short scales. Revue Neurologique, 172(2), 138-45. https://doi.org/10.1016/j.neurol.2015.08.004
Gasser AI, et al. Cognitive Screening in Parkinson's Disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) With 3 Other Short Scales. Rev Neurol (Paris). 2016;172(2):138-45. PubMed PMID: 26494570.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cognitive screening in Parkinson's disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) with 3 other short scales. AU - Gasser,A-I, AU - Calabrese,P, AU - Kalbe,E, AU - Kessler,J, AU - Rossier,P, Y1 - 2015/10/20/ PY - 2015/04/18/received PY - 2015/07/30/revised PY - 2015/08/24/accepted PY - 2015/10/24/entrez PY - 2015/10/24/pubmed PY - 2016/12/15/medline KW - Cognition KW - Cognitive impairment KW - Dementia KW - Démence KW - Dépistage KW - Maladie de Parkinson KW - Neuropsychological assessment KW - Parkinson's disease KW - Screening test KW - Troubles cognitifs SP - 138 EP - 45 JF - Revue neurologique JO - Rev Neurol (Paris) VL - 172 IS - 2 N2 - BACKGROUND: Cognitive screening is crucial in Parkinson's disease (PD). However, there is still a lack of short tools in French. In this study, we aimed to compare the Parkinson Neuropsychometric Dementia Assessment (PANDA) with the Mini Mental Parkinson (MMP), the Mini Mental State Examination (MMSE) and the Clock Test in French-speaking patients. We also aimed to propose cut-off scores for cognitive impairment and dementia for the French language version of the PANDA. METHOD: Fifty-one patients with PD took the PANDA, the MMSE, the MMP, and the Clock Test. They also underwent extensive neuropsychological testing by a neuropsychologist who was blinded to the above-mentioned screening test results. Patients were classified as either having normal cognition (n=15), mild cognitive impairment (n=20) or dementia (n=16). RESULTS: When compared with the three other screening tools, the PANDA exhibited the highest area under the curve (AUC) for both cognitive disorders and dementia. Using the cut-off scores proposed for the German version, the PANDA had 94% specificity and 100% sensitivity for dementia and 100% and 72%, respectively for cognitive disorders. CONCLUSIONS: In our study, the PANDA exhibited a higher discriminative power than the three other tests in detecting cognitive disorders and dementia. In PD patients, the PANDA should thus be considered for the detection of cognitive impairment in routine clinical practice. SN - 0035-3787 UR - https://www.unboundmedicine.com/medline/citation/26494570/Cognitive_screening_in_Parkinson's_disease:_Comparison_of_the_Parkinson_Neuropsychometric_Dementia_Assessment__PANDA__with_3_other_short_scales_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0035-3787(15)00836-X DB - PRIME DP - Unbound Medicine ER -